<SEC-DOCUMENT>0000899140-22-000438.txt : 20220401
<SEC-HEADER>0000899140-22-000438.hdr.sgml : 20220401
<ACCEPTANCE-DATETIME>20220401165344
ACCESSION NUMBER:		0000899140-22-000438
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220330
ITEM INFORMATION:		Entry into a Material Definitive Agreement
FILED AS OF DATE:		20220401
DATE AS OF CHANGE:		20220401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		22799095

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>i51965368.htm
<DESCRIPTION>FORM 8K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: asdf
         Document created using EDGARfilings PROfile 7.7.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="margin-bottom: 6pt;"><br>
    </div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.6pt; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 93.4pt; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 93.4pt; margin-top: 0.65pt; font-size: 8pt; font-weight: bold;">Washington, DC 20549</div>
    <div style="margin-top: 0.65pt; text-align: center;">_______________________________<br>
    </div>
    <div style="margin: 2.85pt 93.6pt 0px 93.4pt; font-size: 18pt; font-weight: bold; text-align: center;">FORM 8-K</div>
    <div style="margin-bottom: 6pt; text-align: center;">_______________________________</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.9pt; margin-top: 4.8pt; font-weight: bold;">CURRENT REPORT</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.75pt; margin-top: 1.1pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
    <div style="text-align: center; margin-right: 93.55pt; margin-left: 93.4pt; margin-top: 1.1pt;">Date of Report (Date of earliest event reported): March 30, 2022</div>
    <div style="text-align: center; margin-right: 93.9pt; margin-left: 92.7pt; margin-top: 2.85pt; font-size: 14pt; font-weight: bold;">INNOVIVA, INC.</div>
    <div style="text-align: center; margin-right: 93.6pt; margin-left: 93.6pt; margin-top: 6pt; margin-bottom: 6pt;">(Exact Name of Registrant as Specified in its Charter)</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1629869689f04105bd0632ca424fa567">

        <tr>
          <td style="width: 33.34%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">Delaware<br>
              (State or Other Jurisdiction of Incorporation)</div>
          </td>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">000-30319<br>
              (Commission&#160; File Number)<br>
              1350 Old Bayshore Highway, Suite 400<br>
              Burlingame, California 94010<br>
              (650) 238-9600</div>
          </td>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="text-align: center; font-size: 8pt; font-weight: bold;">94-3265960<br>
              (I.R.S. Employer Identification Number)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; margin-top: 6pt;">(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)<br>
      (Former name or former address, if changed since last report)</div>
    <div style="text-align: center; margin-top: 6pt; margin-bottom: 6pt;">_______________________</div>
    <div style="text-align: justify; margin-top: 3.7pt; margin-bottom: 6pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
      General Instruction A.2. below):</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zfa4a7b20fafd4fbab968183f1d70883d">

        <tr>
          <td style="width: 7.76%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
          <td style="width: 92.24%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.76%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
          <td style="width: 92.24%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.76%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
          <td style="width: 92.24%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.76%; vertical-align: top; text-align: center;">&#160;&#9744;</td>
          <td style="width: 92.24%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; margin-top: 0.85pt; margin-bottom: 6pt;">Securities registered pursuant to Section 12(b) of the Act:</div>
    <div style="margin-top: 0.85pt; margin-bottom: 6pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z01caf90215d74db9b49b57f0b774d0b8">

        <tr>
          <td style="width: 37.6%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">Title of each class</div>
          </td>
          <td style="width: 24.73%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">Trading Symbol(s)</div>
          </td>
          <td style="width: 37.67%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">Name of each exchange on which registered</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.6%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">Common Stock, par value $0.01 per share</div>
          </td>
          <td style="width: 24.73%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">INVA</div>
          </td>
          <td style="width: 37.67%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: justify;">The NASDAQ Global Select Market</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the
      Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company</div>
    <div style="text-align: justify; margin-top: 6pt; margin-bottom: 6pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 13(a) of the Exchange Act.</div>
    <div style="margin-bottom: 6pt;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin-bottom: 6pt;"><br>
    </div>
    <div style="margin-bottom: 12pt; font-size: 12pt; font-weight: bold;">Item 1.01. Entry into a Material Definitive Agreement</div>
    <div style="text-align: justify; text-indent: 72pt; margin-right: 16.25pt; margin-bottom: 12pt; font-size: 12pt;"><br>
      <br>
      On May 20, 2021, in connection with the repurchase of shares of Innoviva, Inc. (&#8220;<u>Innoviva</u>&#8221;) from Glaxo Group Limited, Innoviva Strategic Partners LLC (&#8220;<u>Strategic Partners</u>&#8221;), a wholly owned subsidiary of Innoviva, received a distribution
      of $110,00,000 from ISP Fund LP (the &#8220;<u>Partnership</u>&#8221;).&#160; Strategic Partners, the Partnership and Sarissa Capital Fund GP LP entered into a letter agreement in connection with such distribution (the &#8220;<u>Letter Agreement</u>&#8221;) pursuant to which,
      among other things, Strategic Partners committed to make a capital contribution to the Partnership in an amount equal to the distribution no later than March 31, 2022.&#160; On March 30, 2022, Strategic Partners made such contribution to the Partnership.
      The contribution was approved by the audit committee of Innoviva&#8217;s Board of Directors.</div>
    <div style="text-align: justify; text-indent: 72pt; margin-right: 16.25pt; margin-bottom: 12pt; font-size: 12pt;">The Letter Agreement was attached as Exhibit 10.2 to the Current Report on Form 8-K filed on May 20, 2021, and is incorporated herein by
      reference.</div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="margin: 0px 0px 12pt; font-family: 'Times New Roman',Times,serif; text-align: center;">SIGNATURE</div>
    <div style="text-indent: 72pt; margin-right: 13.7pt; margin-bottom: 12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
      hereunto duly authorized.</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z800f463595ad4d26bff95d1f5dad9058">

        <tr>
          <td style="width: 47.51%; vertical-align: top;">
            <div style="margin-right: 13.95pt; font-family: 'Times New Roman', Times, serif;">Date: April 1, 2022</div>
          </td>
          <td style="width: 52.49%; vertical-align: top;">
            <div style="text-indent: -19.2pt; margin-left: 19.2pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">INNOVIVA, INC.</div>
            <div>&#160;</div>
            <div style="text-indent: -19.2pt; margin-left: 19.2pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">By:&#160;<u> /s/ Pavel Raifeld &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; <font style="display: inline-block; text-indent: 0px; font-size: 1px; width: 12pt" id="TRGRRTFtoHTMLTab"></font></u><br>
              Pavel Raifeld<br>
              Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 0.9pt; margin-bottom: 12pt;"><br>
    </div>
    <div style="margin-top: 0.9pt; margin-bottom: 12pt;"><br>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
